Second megaround of ‘19 to help Passage broaden rare CNS disease pipeline

The gene therapy team and scientific foundation behind Passage Bio continue to attract investors, as the company said Wednesday it had raised $110 million in a series B round led by Access Biotechnology.

The investment comes less than seven months after the February launch of Passage

Read the full 453 word article

How to gain access

Continue reading with a
two-week free trial.